Examining the differences in current regulatory processes for sunscreens and proposed safety assessment paradigm

Edward V. Sargent, Jeffrey Travers

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Skin cancers including malignant melanoma which are due to UV radiation constitute a serious public health problem. Recent studies have confirmed the importance of UVA radiation in the pathogenesis of skin cancer, as well as the protective effects of broad-spectrum sunscreen use. Barriers for effective protection of the US public include the lack of effective UV filters, especially in the UVA spectrum. The major reason for the paucity of UVA-effective filters in the US is due primarily to the FDA's reluctance to approve agents which have already been on the market in Europe and elsewhere in the world for more than a decade. The underlying reasons for these discrepancies in new sunscreen approval success between the US and abroad are complex, and include factors such as that the FDA considers UV filters as drugs, whereas they are regulated as cosmetics elsewhere. FDA has not as yet developed a consistent approach for the approval of new UV filters. We provide a paradigm for both non-clinical testing and human safety testing which includes parameters for a human maximum use test (MUsT) that is based upon both ethical and scientific concepts. These suggestions could form the basis of future regulatory guidelines for rational testing thus allowing us to reach the consensus goal of more efficient and timely approval of much-needed UV filters to provide protection for the US public.

Original languageEnglish (US)
JournalRegulatory Toxicology and Pharmacology
DOIs
StateAccepted/In press - 2016
Externally publishedYes

Fingerprint

Sun hoods
Sunscreening Agents
Skin Neoplasms
Skin
Safety testing
Radiation
Safety
Cosmetics
Testing
Public health
Medical problems
Ultraviolet radiation
Melanoma
Public Health
Guidelines
Pharmaceutical Preparations

Keywords

  • Human
  • Non-clinical
  • Safety testing
  • Skin cancer
  • Sunscreens
  • UV filters

ASJC Scopus subject areas

  • Toxicology

Cite this

@article{2495ee530a0f48928440bc2fd3fe5cab,
title = "Examining the differences in current regulatory processes for sunscreens and proposed safety assessment paradigm",
abstract = "Skin cancers including malignant melanoma which are due to UV radiation constitute a serious public health problem. Recent studies have confirmed the importance of UVA radiation in the pathogenesis of skin cancer, as well as the protective effects of broad-spectrum sunscreen use. Barriers for effective protection of the US public include the lack of effective UV filters, especially in the UVA spectrum. The major reason for the paucity of UVA-effective filters in the US is due primarily to the FDA's reluctance to approve agents which have already been on the market in Europe and elsewhere in the world for more than a decade. The underlying reasons for these discrepancies in new sunscreen approval success between the US and abroad are complex, and include factors such as that the FDA considers UV filters as drugs, whereas they are regulated as cosmetics elsewhere. FDA has not as yet developed a consistent approach for the approval of new UV filters. We provide a paradigm for both non-clinical testing and human safety testing which includes parameters for a human maximum use test (MUsT) that is based upon both ethical and scientific concepts. These suggestions could form the basis of future regulatory guidelines for rational testing thus allowing us to reach the consensus goal of more efficient and timely approval of much-needed UV filters to provide protection for the US public.",
keywords = "Human, Non-clinical, Safety testing, Skin cancer, Sunscreens, UV filters",
author = "Sargent, {Edward V.} and Jeffrey Travers",
year = "2016",
doi = "10.1016/j.yrtph.2016.03.008",
language = "English (US)",
journal = "Regulatory Toxicology and Pharmacology",
issn = "0273-2300",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Examining the differences in current regulatory processes for sunscreens and proposed safety assessment paradigm

AU - Sargent, Edward V.

AU - Travers, Jeffrey

PY - 2016

Y1 - 2016

N2 - Skin cancers including malignant melanoma which are due to UV radiation constitute a serious public health problem. Recent studies have confirmed the importance of UVA radiation in the pathogenesis of skin cancer, as well as the protective effects of broad-spectrum sunscreen use. Barriers for effective protection of the US public include the lack of effective UV filters, especially in the UVA spectrum. The major reason for the paucity of UVA-effective filters in the US is due primarily to the FDA's reluctance to approve agents which have already been on the market in Europe and elsewhere in the world for more than a decade. The underlying reasons for these discrepancies in new sunscreen approval success between the US and abroad are complex, and include factors such as that the FDA considers UV filters as drugs, whereas they are regulated as cosmetics elsewhere. FDA has not as yet developed a consistent approach for the approval of new UV filters. We provide a paradigm for both non-clinical testing and human safety testing which includes parameters for a human maximum use test (MUsT) that is based upon both ethical and scientific concepts. These suggestions could form the basis of future regulatory guidelines for rational testing thus allowing us to reach the consensus goal of more efficient and timely approval of much-needed UV filters to provide protection for the US public.

AB - Skin cancers including malignant melanoma which are due to UV radiation constitute a serious public health problem. Recent studies have confirmed the importance of UVA radiation in the pathogenesis of skin cancer, as well as the protective effects of broad-spectrum sunscreen use. Barriers for effective protection of the US public include the lack of effective UV filters, especially in the UVA spectrum. The major reason for the paucity of UVA-effective filters in the US is due primarily to the FDA's reluctance to approve agents which have already been on the market in Europe and elsewhere in the world for more than a decade. The underlying reasons for these discrepancies in new sunscreen approval success between the US and abroad are complex, and include factors such as that the FDA considers UV filters as drugs, whereas they are regulated as cosmetics elsewhere. FDA has not as yet developed a consistent approach for the approval of new UV filters. We provide a paradigm for both non-clinical testing and human safety testing which includes parameters for a human maximum use test (MUsT) that is based upon both ethical and scientific concepts. These suggestions could form the basis of future regulatory guidelines for rational testing thus allowing us to reach the consensus goal of more efficient and timely approval of much-needed UV filters to provide protection for the US public.

KW - Human

KW - Non-clinical

KW - Safety testing

KW - Skin cancer

KW - Sunscreens

KW - UV filters

UR - http://www.scopus.com/inward/record.url?scp=84970045563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970045563&partnerID=8YFLogxK

U2 - 10.1016/j.yrtph.2016.03.008

DO - 10.1016/j.yrtph.2016.03.008

M3 - Article

JO - Regulatory Toxicology and Pharmacology

JF - Regulatory Toxicology and Pharmacology

SN - 0273-2300

ER -